Saturday 17 October 2026 Export PTPI’s income statement to Excel — free account

Petros Pharmaceuticals, Inc.

PTPI Healthcare Drug Manufacturers Specialty & Generic

In the quarter to June 2026, revenue grew 1,070.6%, EPS grew 76.7% and free cash flow grew 71.3%, each against the same quarter a year earlier.

0.00 0.00 NaN

Follow PTPI

Alert me

Market cap: $1.0M
P/E: 0.0×
Fwd P/E: −0.3×
Dividend yield: —
F-score: 4/9
Altman Z: −16.96
Beneish M: −3.26
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 46.19%

Capital & Financial Ratios $m

Market Cap 1.04

Revenue 7.92

Net Income (3.20)

Free Cash Flow (3.72)

Net Debt (3.49)

Current Ratio 1.25

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.30)

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 67.43%

Next Y EPS Growth 48.83%

Next Y revenue growth 7.10%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

EV/Sales against its own 10 years 27.88%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	13	2	5	3
Receivables	2	0	—	—
Inventory	2	1	—	—
Other	—	6	—	—
	20	7	5	4

	2023	2024	2025	Q'26
Payables	2	1	0	0
ST’ Debt	—	—	—	—
Other	0	15	0	—
	11	18	2	3

Compound Annual Growth %

	10y	5y	3y
Sales	—	(19.98%)	(13.18%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(13.17%)	(30.31%)	(44.40%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	1	1	2	4	5
’23	3	2	2	—	6
’22	2	4	—	1	6
’21	4	2	2	(1)	8
’20	2	1	3	3	10
’19	5	4	—	—	16

Fiscal quarters ending in the months shown.

value withheld pending a data check

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(2)	(3)	(1)	(1)	(7)
’24	(1)	(2)	(1)	1	(3)
’23	(1)	(1)	(4)	(2)	(8)
’22	(5)	(4)	(2)	(2)	(13)
’21	0	(2)	(1)	(8)	(12)
’20	(2)	(6)	(3)	(5)	(15)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(2)	(3)	(1)	(1)	(7)
’24	(1)	(2)	(1)	1	(3)
’23	(1)	(1)	(4)	(2)	(8)
’22	(5)	(4)	(2)	(2)	(13)
’21	0	(2)	(1)	(8)	(12)
’20	(2)	(6)	(3)	(5)	(15)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.02)	(0.30)	—	—	—
’25	(9.37)	(1.29)	(0.03)	1.83	(1.56)
’24	(42.25)	(9.25)	(13.25)	(29.00)	(83.50)
’23	(16.50)	(30.00)	(57.75)	(54.25)	(158.75)
’22	(2.50)	(22.50)	(167.50)	(50.80)	(242.00)
’21	77.50	(55.00)	(42.50)	(187.50)	(207.50)
’20	(307.23)	(419.53)	(240.20)	3.39	(963.58)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	450.00	297.50	47.75	22.93	5.53	0.00	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	1,490.00	1,300.00	905.00	238.50	56.75	16.25
People
People	Employees	5	5	8	7	27	24	24	21	18	3
	Revenue/emp, $m	0.00	0.00	1.76	2.23	0.35	0.33	0.25	0.28	0.28	0.00
Income, $m
Income, $m	Revenue	—	—	14	16	10	8	6	6	5	—
	Gross margin, %	—	—	25.41	52.32	57.67	79.52	61.79	71.98	76.28	—
	EBT	(13)	(13)	(11)	(33)	(22)	(9)	(20)	(8)	(1)	(4)
	EBT margin, %	0.00	0.00	(78.44)	(212.86)	(230.27)	(115.05)	(334.40)	(140.20)	(13.79)	0.00
	Net income	(13)	(13)	(11)	(33)	(21)	(9)	(20)	(8)	(14)	2
	Depreciation	0	0	0	10	7	7	13	3	6	—
Per share, $
Per share, $	Revenue	0.00	0.00	2,195.50	1,589.51	446.71	179.16	72.37	66.92	15.93	0.00
	Earnings	(7,112.50)	(2,025.42)	(1,712.50)	(3,303.99)	(877.85)	(207.50)	(242.05)	(158.75)	(83.50)	(1.56)
	Cash flow	(4,098.06)	(1,772.27)	(1,202.62)	258.42	(715.20)	(272.06)	(154.56)	(87.66)	(8.11)	(0.24)
	Capex	(1.61)	(0.58)	(0.50)	(7.30)	(0.21)	0.00	0.00	0.00	(0.08)	0.00
	Free cash flow	(4,099.67)	(1,772.85)	(1,203.12)	251.12	(715.42)	(272.06)	(154.56)	(87.66)	(8.19)	(0.24)
	Book value	13,113.72	2,400.97	4,143.95	818.29	816.31	815.25	201.72	138.75	(23.26)	0.10
	Shares, m	0	0	0	0	0	0	0	0	0	28
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
	P/S	—	—	0.00	0.00	2.46	4.65	1.10	0.53	0.40	—
	P/B	—	—	0.02	0.00	1.35	1.02	0.40	0.26	0.00	—
	EV/Sales	—	—	0.00	0.00	1.48	1.87	1.22	(0.28)	1.02	—
	EV/FCF	—	—	3.67	4.81	(0.92)	(1.23)	(0.57)	0.22	(3.08)	—
Cash, $m
Cash, $m	Operating cash flow	(7)	(11)	(8)	3	(15)	(12)	(13)	(8)	(3)	(7)
	Capex	0	0	0	0	0	—	—	—	0	—
	Free cash flow	(7)	(11)	(8)	2	(15)	(12)	(13)	(8)	(3)	(7)
Balance, $m
Balance, $m	Working capital	24	15	27	(29)	(16)	0	8	10	(11)	3
	Total debt	—	—	47	14	8	0	8	7	—	—
	Net debt	(26)	(16)	18	12	(9)	(23)	(1)	(6)	(2)	(5)
	Shareholders’ equity	24	15	27	8	17	36	17	12	(7)	3
Returns, %
Returns, %	ROA	(66.71)	(59.49)	(48.00)	(74.02)	(32.11)	(13.10)	(40.15)	(41.72)	(120.62)	(553.07)
	ROIC	0.00	0.00	(15.53)	(61.53)	(134.43)	(93.20)	(79.46)	(152.21)	0.00	0.00
	ROE	(109.61)	(65.55)	(53.24)	(447.74)	(752.67)	(33.90)	(76.70)	(96.02)	(1,164.24)	1,900.89

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2024 · latest quarter Dec 2024

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
AKAN Akanda Corp.	$3.5M	—	—	—	—	−472.01% (below 0%: shrinking)	(197.87%)	0.00%	Compare
PRFX PainReform Ltd.	$2.6M	— (loss-making)	— (loss-making)	—	n/m	+52.56% (above 0%: growing)	0.00%	0.00%	Compare
BTAIQ BioXcel Therapeutics, Inc.	$2.3M	— (loss-making)	— (loss-making)	+51.67% (above 0%: growing)	n/m	+51.51% (above 0%: growing)	87.91%	(5,600.55%)	Compare
IMCC IM Cannabis Corp.	$2.2M	— (loss-making)	— (loss-making)	−40.28% (below 0%: shrinking)	n/m	−266.81% (below 0%: shrinking)	19.83%	(27.54%)	Compare
NEPTF Neptune Wellness Solutions Inc.	$1.6M	— (loss-making)	— (loss-making)	−37.75% (below 0%: shrinking)	n/m	+53.44% (above 0%: growing)	13.62%	(232.88%)	Compare
PTPI Petros Pharmaceuticals, Inc.	$1.0M	— (loss-making)	— (loss-making)	+1,070.55% (above 0%: growing)	n/m	+71.27% (above 0%: growing)	73.82%	0.00%
SBFM Sunshine Biopharma, Inc.	$990.0K	— (loss-making)	— (loss-making)	−1.56% (below 0%: shrinking)	n/m	+49.38% (above 0%: growing)	26.20%	(17.41%)	Compare
LSDIF Lucy Scientific Discovery Inc.	$900.0K	— (loss-making)	—	—	n/m	−493.98% (below 0%: shrinking)	59.79%	(8,891.75%)	Compare
SXTC China SXT Pharmaceuticals, Inc.	$710.0K	— (loss-making)	— (loss-making)	−16.76% (below 0%: shrinking)	+92.67% (above 0%: growing)	−107.59% (below 0%: shrinking)	44.09%	0.00%	Compare
Median of peers	$1.9M	—	—	−16.76%	—	−29.11%	23.02%	(22.47%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Petros Pharmaceuticals, Inc. (PTPI) key facts

Petros Pharmaceuticals, Inc. (PTPI) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector.
Return on equity was 1,900.9% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −16.96 (distress zone) for fiscal 2024.

Source: company filings (standardised) and stockrow calculations.